PRF-110 Matches Approved Benchmark, Shows Favorable PK in Expanded Preclinical Study
PRFX sits 16% above its 52-week low of $1.28 on light trading volume (0.1× avg).
Summary
PRF Technologies announced expanded preclinical results for its lead candidate, PRF-110, demonstrating analgesic efficacy comparable to the approved benchmark ZYNRELEF. The study also revealed a favorable pharmacokinetic profile for PRF-110, characterized by slower absorption and enhanced local tissue retention. This update follows initial positive preclinical results reported on May 26th, providing more detailed comparative data. For this clinical-stage micro-cap, these findings further validate PRF-110's potential as a differentiated, long-acting post-operative pain solution.
At the time of this announcement, PRFX was trading at $1.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $1.28 to $17.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.